Indini Alice, Nigro Olga, Lengyel Csongor György, Ghidini Michele, Petrillo Angelica, Lopez Salvatore, Raspagliesi Francesco, Trapani Dario, Khakoo Shelize, Bogani Giorgio
Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy.
Medical Oncology, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, 21100 Varese, Italy.
Cancers (Basel). 2021 Apr 1;13(7):1663. doi: 10.3390/cancers13071663.
Platinum-resistant ovarian cancer (OC) has limited treatment options and is associated with a poor prognosis. There appears to be an overlap between molecular mechanisms responsible for platinum resistance and immunogenicity in OC. Immunotherapy with single agent checkpoint inhibitors has been evaluated in a few clinical trials with disappointing results. This has prompted exploration of immunotherapy combination strategies with chemotherapy, anti-angiogenics, poly (ADP-ribose) polymerase (PARP) inhibitors and other targeted agents. The role of immunotherapy in the treatment of platinum-resistant OC remains undefined. The aim of this review is to describe the immunobiology of OC and likely benefit from immunotherapy, discuss clinical trial data and biomarkers that warrant further exploration, as well as provide an overview of future drug development strategies.
铂耐药卵巢癌（OC）的治疗选择有限，且预后较差。在OC中，负责铂耐药和免疫原性的分子机制之间似乎存在重叠。单药检查点抑制剂免疫疗法已在一些临床试验中进行了评估，但结果令人失望。这促使人们探索免疫疗法与化疗、抗血管生成药物、聚（ADP-核糖）聚合酶（PARP）抑制剂及其他靶向药物的联合策略。免疫疗法在铂耐药OC治疗中的作用仍不明确。本综述的目的是描述OC的免疫生物学以及可能从免疫疗法中获益的情况，讨论值得进一步探索的临床试验数据和生物标志物，并概述未来的药物开发策略。
